CN104870013A - 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 - Google Patents

用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 Download PDF

Info

Publication number
CN104870013A
CN104870013A CN201280075412.0A CN201280075412A CN104870013A CN 104870013 A CN104870013 A CN 104870013A CN 201280075412 A CN201280075412 A CN 201280075412A CN 104870013 A CN104870013 A CN 104870013A
Authority
CN
China
Prior art keywords
antibody
cxcl10
cxcl9
cxcr3
cxcl11
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280075412.0A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·W·利拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ji'ante Technology Co
Morehouse School of Medicine Inc
Original Assignee
Ji'ante Technology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ji'ante Technology Co filed Critical Ji'ante Technology Co
Priority to CN201710770034.2A priority Critical patent/CN112807427A/zh
Publication of CN104870013A publication Critical patent/CN104870013A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
CN201280075412.0A 2012-06-27 2012-06-27 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 Pending CN104870013A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710770034.2A CN112807427A (zh) 2012-06-27 2012-06-27 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/044464 WO2014003742A1 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710770034.2A Division CN112807427A (zh) 2012-06-27 2012-06-27 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途

Publications (1)

Publication Number Publication Date
CN104870013A true CN104870013A (zh) 2015-08-26

Family

ID=49783685

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280075412.0A Pending CN104870013A (zh) 2012-06-27 2012-06-27 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
CN201710770034.2A Pending CN112807427A (zh) 2012-06-27 2012-06-27 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710770034.2A Pending CN112807427A (zh) 2012-06-27 2012-06-27 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途

Country Status (5)

Country Link
EP (1) EP2866830A4 (ja)
JP (1) JP2015524793A (ja)
CN (2) CN104870013A (ja)
HK (1) HK1212628A1 (ja)
WO (1) WO2014003742A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107236023A (zh) * 2017-05-12 2017-10-10 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
CN109777784A (zh) * 2019-02-22 2019-05-21 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
CN110511912A (zh) * 2018-08-30 2019-11-29 上海斯丹赛生物技术有限公司 免疫细胞的功能调节

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944811C (en) * 2014-04-08 2022-06-21 Urs Christen Combination therapy for the treatment of autoimmune diseases
CN105039319A (zh) * 2015-06-22 2015-11-11 浙江理工大学 用于预测乳腺癌新辅助化疗疗效的生物标记物和荧光定量免疫pcr试剂盒
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2019103541A1 (ko) * 2017-11-24 2019-05-31 서울대학교 산학협력단 그래핀 나노구조체를 포함하는 항염증용 조성물
EP4009858A1 (en) 2019-08-07 2022-06-15 Edifice Health, Inc. Treatment of prevention of cardiovascular disease
EP3960861A1 (en) * 2020-08-31 2022-03-02 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers that target cxcl9
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用
TW202345871A (zh) * 2022-03-30 2023-12-01 美商旗艦先鋒創新公司 Cxcl調節組合物及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
CN101842115A (zh) * 2007-08-29 2010-09-22 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288305T3 (es) * 1996-09-10 2008-01-01 Theodor-Kocher Institute Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso.
US9963504B2 (en) * 2010-09-02 2018-05-08 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
WO2012082494A2 (en) * 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
CN101842115A (zh) * 2007-08-29 2010-09-22 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. BUSUTTIL: "CXCR3 ligands are augmented during the", 《EUROPEAN RESPIRATORY JOURNAL》 *
SEBASTIAN SCHROEPF ET AL.: "Strong Overexpression of CXCR3 Axis Components in Childhood Inflammatory Bowel Disease", 《INFLAMM BOWEL DIS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107236023A (zh) * 2017-05-12 2017-10-10 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
CN110511912A (zh) * 2018-08-30 2019-11-29 上海斯丹赛生物技术有限公司 免疫细胞的功能调节
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
CN109777784A (zh) * 2019-02-22 2019-05-21 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
CN109777784B (zh) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用

Also Published As

Publication number Publication date
HK1212628A1 (zh) 2016-06-17
WO2014003742A1 (en) 2014-01-03
JP2015524793A (ja) 2015-08-27
EP2866830A1 (en) 2015-05-06
CN112807427A (zh) 2021-05-18
EP2866830A4 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
CN104870013A (zh) 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
Lowes et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Yuan et al. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis
JP6550092B2 (ja) 自己免疫疾患の治療及び／又は診断におけるアプタマーの使用
CN104994858A (zh) Tec家族激酶抑制剂辅助疗法
US20160130350A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
KR20080081069A (ko) 만성 섬유성 질환을 치료하기 위한 물질 및 방법
JPH06500229A (ja) 擬人化ｃｄｒ移植抗ｉｃａｍ―１抗体、その生産方法及びその使用
US7722886B2 (en) Compositions and methods for treatment of severe acute respiratory syndrome (SARS)
Medvedeva et al. Semax, an analog of ACTH (4− 7), regulates expression of immune response genes during ischemic brain injury in rats
US20220220223A1 (en) Treatment of allergic diseases with chimeric protein
TWI654996B (zh) 微核糖核酸let-7及轉形生長因子β第三類受體調控軸作為心臟損傷標的之用途
CN112367994A (zh) 诊断和治疗表达高水平TGF-β应答标记的癌症患者的方法
AU2019288635A1 (en) Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
KR101837856B1 (ko) 뎅기바이러스 혈청형 2 및 3의 메틸트랜스퍼라제 활성을 억제하는 rna 앱타머
CN106661105B (zh) 用il-20拮抗剂治疗炎性疼痛
US11597772B2 (en) Obinutuzumab treatment of a DLBCL patient subgroup
EP3490675A1 (en) Gamma delta t cells as a target for treatment of solid tumors
KR101604169B1 (ko) Ｔｈ17세포 관련 면역질환 치료를 위한 ＲＯＲα의 용도
US20230192894A1 (en) Methods and compositions for antibody to high affinity receptor for ige
JP2023506253A (ja) 神経筋障害を治療するため組成物及び方法
Askanase et al. New and future therapies: Changes in the therapeutic armamentarium for SLE
KR101837855B1 (ko) 뎅기바이러스 혈청형 2의 메틸트랜스퍼라제 활성을 억제하는 rna 앱타머
EP3845246A1 (en) Medicine for preventing and/or treating stress load-related disease
Chu et al. Therapeutic Applications: Strategies and Molecules Targeting the IL-17/Th17 Pathway

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212628

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150826

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1212628

Country of ref document: HK